Oxidative stress in vascular dementia and alzheimer's disease: A common pathology

Journal of Alzheimer's Disease

Volumn 17, Issue 2, 2009, Pages 245-257

  Bennett, Stuart ^a   Grant, Melissa M ^a   Aldred, Sarah ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Atherosclerosis; Dementia; Reactive oxygen species; Vascular dysfunction

Indexed keywords

AMYLOID BETA PROTEIN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; ATHEROSCLEROTIC PLAQUE; BRAIN BLOOD FLOW; ENDOTHELIAL DYSFUNCTION; MULTIINFARCT DEMENTIA; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VASCULAR DISEASE;

EID: 67849097738     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-1041     Document Type: Review

References (101)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dementia 3, 186-191.
2. van OM, de Jong FJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM (2007) Atherosclerosis and risk for dementia. Ann Neurol 61, 403-410.
3. Singh U, Jialal I (2006) Oxidative stress and atherosclerosis. Pathophysiology 13, 129-142.
4. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van HF, van Duijn CN, Van BC, Grobbee DE (1997) Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study Lancet 349, 151-154.
5. Ott A, Stolk RP, Hofman A, van HF, Grobbee DE, Breteler MM (1996) Association of diabetes mellitus and dementia: the Rotterdam Study Diabetologia 39, 1392-1397.
6. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR (1997) Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277, 813-817.
7. Roy S, Rauk A (2005) Alzheimer's disease and the 'ABSENT' hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity Med Hypotheses 65, 123-137.
8. Launer LJ (2002) Demonstrating the case that AD is a vascular disease: epidemiologic evidence. Ageing Res Rev 1, 61-77.
9. Harman D (1956) Aging: a theory based on free radical and radiation chemistry. J Gerontol 11, 298-300.
10. Beckman KB, Ames BN (1998) The free radical theory of aging matures. Physiol Rev 78, 547-581.
11. Bokov A, Chaudhuri A, Richardson A (2004) The role of oxidative damage and stress in aging. Mech Ageing Dev 125, 811-826.
12. Sies H (1997) Oxidative stress: oxidants and antioxidants. Exp Physiol 82, 291-295.
13. Chapple IL, Matthews JB (2007) The role of reactive oxygen and antioxidant species in periodontal tissue destruction. Periodontol 2000 2007; 43, 160-232.
14. Bedard K, Krause KH (2007) The NOX family of ROS- generating NADPH oxidases: physiology and pathophysiol- ogy. Physiol Rev 87, 245-313.
15. Kamata H, Hirata H (1999) Redox regulation of cellular signalling. Cell Signal 11, 1-14.
16. Buss H, Chan TP, Sluis KB, Domigan NM, Winterbourn CC (1997) Protein carbonyl measurement by a sensitive ELISA method. Free Radic Biol Med 23, 361-366.
17. Berlett BS, Stadtman ER (1997) Protein oxidation in aging, disease, and oxidative stress. JBiol Chem 272, 20313-20316.
18. Pratico D, Rokach J, Lawson J, FitzGerald GA (2004) F2- isoprostanes as indices of lipid peroxidation in inflammatory diseases. ChemPhys Lipids 128, 165-171.
19. Butterfield DA, Drake J, Pocernich C, Castegna A (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med 7, 548-554.
20. Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR (2001) Protein oxidation in the brain in Alzheimer's disease. Neuroscience 103, 373-383.
21. Butterfield DA, Lauderback CM (2002) Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide- associated free radical oxidative stress. Free Radic Biol Med 32, 1050-1060.
22. Lovell MA, Markesbery WR (2007) Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res 35, 7497-7504.
23. Markesbery WR, Lovell MA (2007) Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch Neurol 64, 954-956.
24. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 33, 562-571.
25. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase- related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82, 1524-1532.
26. Butterfield DA, Poon HF, St CD, Keller JN, Pierce WM, Klein JB, Markesbery WR (2006) Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis 22, 223-232.
27. Reed TT, Pierce WM, Jr., Turner DM, Markesbery WR, Butterfield DA (2009) Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule. J Cell Mol Med, in press.
28. Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, Coccia R, Markesbery WR, Butterfield DA (2008) Redox proteomic identification of 4-hydroxy-2-nonenal- modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis ofAlzheimer's disease. Neurobiol Dis 30, 107-120.
29. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G (1997) Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17, 2653-2657.
30. Butterfield DA, Reed TT, Perluigi M, De MC, Coccia R, Keller JN, Markesbery WR, Sultana R (2007) Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res 1148, 243-248.
31. Mastrogiacoma F, Lindsay JG, Bettendorff L, Rice J, Kish SJ (1996) Brain protein and alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease. Ann Neurol 39, 592-598.
32. Sorbi S, Bird ED, Blass JP (1983) Decreased pyruvate de- hydrogenase complex activity in Huntington and Alzheimer brain. Ann Neurol 13, 72-78.
33. Parker WD, Jr., Parks J, Filley CM, Kleinschmidt-DeMasters BK (1994) Electron transport chain defects in Alzheimer's disease brain. Neurology 44, 1090-1096.
34. Davis RE, Miller S, Herrnstadt C, Ghosh SS, Fahy E, Shinobu LA, Galasko D, Thal LJ, Beal MF, Howell N, Parker WD, Jr. (1997) Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc Natl AcadSci USA 94, 4526-4531.
35. Devi L, Prabhu BM, Galati DF, Avadhani NG, Anan-datheerthavarada HK (2006) Accumulation of amyloid precursor protein in the mitochondrial import channels ofhuman Alzheimer's disease brain is associated with mitochondrial dysfunction. JNeurosci 26, 9057-9068.
36. Wilkinson BL, Landreth GE (2006) The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. JNeuroinflammation 3, 30.
37. Bianca VD, Dusi S, Bianchini E, Dal P, I, Rossi F (1999) beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism ofneuronal damage in Alzheimer's disease. JBiolChem 274, 15493-15499.
38. Shimohama S, Tanino H, Kawakami N, Okamura N, Kodama H, Yamaguchi T, Hayakawa T, Nunomura A, Chiba S, Perry G, Smith MA, Fujimoto S (2000) Activation of NADPH oxidase in Alzheimer's disease brains. Biochem Biophys Res Commun 273, 5-9.
39. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL,Markesbery WR (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. JNeurol Sci 158, 47-52.
40. Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430, 631-639.
41. Steele M, Stuchbury G, Munch G (2007) The molecular basis of the prevention of Alzheimer's disease through healthynutrition. Exp Gerontol 42, 28-36.
42. Zini I, Tomasi A, Grimaldi R, Vannini V, Agnati LF (1992) Detection offree radicals during brain ischemia and reperfu- sion by spin trapping and microdialysis. Neurosci Lett 138, 279-282.
43. Sinclair AJ, Bayer AJ, Johnston J, Warner C, Maxwell SR (1998) Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int J Geriatr Psychiatry 13, 840-845.
44. Ryglewicz D, Rodo M, Kunicki PK, Bednarska-Makaruk M, Graban A, Lojkowska W, Wehr H (2002) Plasma antioxidant activity and vascular dementia. J Neurol Sci 203-204, 195-197.
45. Polidori MC, Mattioli P, Aldred S, Cecchetti R, Stahl W, Griffiths H, Senin U, Sies H, Mecocci P (2004) Plasma an- tioxidant status, immunoglobulin g oxidation and lipid per- oxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dement Geriatr Cogn Disord18, 265-270.
46. Casado A, Encarnacion Lopez-Fernandez M, Concepcion CM, de La TR (2008) Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neu-rochem Res 33, 450-458.
47. Gackowski D, Rozalski R, Siomek A, Dziaman T, Nicpon K, Klimarczyk M, Araszkiewicz A, Olinski R (2008) Oxidative stress and oxidative DNA damage is characteristic for mixed Alzheimer disease/vascular dementia. J Neurol Sci 266, 57-62.
48. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H (2003) Role of oxidative stress in atherosclerosis. Am J Cardiol 91, 7A-11A.
49. Heijnen HF, van DE, Slot JW, Fries DM, Blachard-Fillion B, Hodara R, Lightfoot R, Polydoro M, Spielberg D, Thomson L, Regan EA, Crapo J, Ischiropoulos H (2006) Subcellular localization of tyrosine-nitrated proteins is dictated by reactive oxygen species generating enzymes and by proximity to nitric oxide synthase. Free Radic Biol Med 40, 1903-1913.
50. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG (2003) Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. JClin Invest 111, 1201-1209.
51. Guzik TJ, Harrison DG (2006) Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today11, 524-533.
52. Pennathur S, Heinecke JW (2007) Oxidative stress and en- dothelial dysfunction in vascular disease. Curr Diab Rep 7, 257-264.
53. Luth HJ, Munch G, Arendt T (2002) Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res 953, 135-143.
54. Maxwell AJ (2002) Mechanisms ofdysfunction ofthe nitric oxide pathway in vascular diseases. Nitric Oxide 6, 101-124.
55. Dorheim MA, Tracey WR, Pollock JS, Grammas P (1994) Nitric oxide synthase activity is elevated in brain microves- sels in Alzheimer's disease. Biochem Biophys Res Commun 205, 659-665.
56. Taniyama Y, Griendling KK (2003) Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42, 1075-1081.
57. Nagata K, Saito H, Ueno T, Sato M, Nakase T, Maeda T, Satoh Y, Komatsu H, Suzuki M, Kondoh Y (2007) Clinical diagnosis ofvascular dementia. JNeurol Sci 257, 44-48.
58. Newman AB, Fitzpatrick AL, Lopez O, Jackson S, Lyketsos C, Jagust W, Ives D, Dekosky ST, Kuller LH (2005) Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc 53, 1101-1107.
59. Roman GC (2003) Vascular dementia: distinguishing characteristics, treatment, and prevention. J Am Geriatr Soc 51, S296-S304.
60. Saido TC, Yokota M, Maruyama K, Yamao-Harigaya W, Tani E, Ihara Y, Kawashima S (1994) Spatial resolution of the primary beta-amyloidogenic process induced in postischemic hippocampus. JBiol Chem 269, 15253-15257.
61. Bennett SA, Pappas BA, Stevens WD, Davidson CM, Fortin T, Chen J (2000) Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol Aging 21, 207-214.
62. Qi JP, Wu H, Yang Y, Wang DD, Chen YX, Gu YH, Liu T (2007) Cerebral ischemia and Alzheimer's disease: the expression of amyloid-beta and apolipoprotein E in human hippocampus. JAlzheimers Dis 12, 335-341.
63. Wen Y, Onyewuchi O, Yang S, Liu R, Simpkins JW (2004) Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Brain Res 1009, 1-8.
64. Tamagno E, Bardini P, Obbili A, Vitali A, Borghi R, Zaccheo D, Pronzato MA, Danni O, Smith MA, Perry G, Tabaton M (2002) Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 10, 279-288.
65. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M (1996) beta-Amyloid-mediated vasoactivity and vascular en- dothelial damage. Nature 380, 168-171.
66. Suo Z, Tan J, Placzek A, Crawford F, Fang C, Mullan M: (1998) Alzheimer's beta-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. Brain Res 807, 110-117.
67. Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C (2001) A beta-peptides enhance vasoconstriction in cerebral circulation. Am Physiol Heart Circ Physiol 281, H2417-H2424.
68. Iadecola C (2003) Atherosclerosis and neurodegeneration: unexpected conspirators in Alzheimer's dementia. Arte- rioscler Thromb VascBiol 23, 1951-1953.
69. Iadecola C (2004) Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 5, 347-360.
70. Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD (1999) Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet 354, 919-920.
71. Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, Seward JD, Sue LI, Beach TG (2003) Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arte-rioscler Thromb Vasc Biol 23, 2055-2062.
72. Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23, 134-147.
73. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. Neurochem 68, 2092-2097.
74. Prohovnik I, Mayeux R, Sackeim HA, Smith G, Stern Y, Alderson PO (1988) Cerebral perfusion as a diagnostic marker of early Alzheimer's disease. Neurology 38, 931-937.
75. Crawford JG (1998) Alzheimer's disease risk factors as related to cerebral blood flow: additional evidence. Med Hy potheses 50, 25-36.
76. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL(1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl Med 320, 915-924.
77. Witztum JL, Steinberg D (1991) Role ofoxidized low density lipoprotein in atherogenesis. Clin Invest 88, 1785-1792.
78. Holvoet P, Collen D (1994) Oxidized lipoproteins in atherosclerosis and thrombosis. FASEB 8, 1279-1284.
79. Parthasarathy S, Quinn MT, Schwenke DC, Carew TE, Steinberg D (1989) Oxidative modification of beta-very low density lipoprotein. Potential role in monocyte recruitment and foam cell formation. Arteriosclerosis 9, 398-404.
80. Schippling S, Kontush A, Arlt S, Buhmann C, Sturenburg HJ, Mann U, Muller-Thomsen T, Beisiegel U (2000) Increased lipoprotein oxidation in Alzheimer's disease. Free Radic Biol Med 28, 351-360.
81. Schulz B, Liebisch G, Grandl M, Werner T, Barlage S, Schmitz G (2007) Beta-amyloid (Abeta40, Abeta42) binding to modified LDL accelerates macrophage foam cell formation. Biochim Biophys Acta 1771, 1335-1344.
82. Griffiths HR, Aldred S, Dale C, Nakano E, Kitas GD, Grant MG, Nugent D, Taiwo FA, Li L, Powers HJ (2006) Homo- cysteine from endothelial cells promotes LDL nitration and scavenger receptor uptake. Free Radic Biol Med 40, 488-500.
83. Selley ML (2003) Increased concentrations of homocys- teine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol Aging 24, 903-907.
84. Koseoglu E, Karaman Y (2007) Relations between homo- cysteine, folate and vitamin B12 in vascular dementia and in Alzheimer disease. Clin Biochem 40, 859-863.
85. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM (1998) Folate, vitamin B12, and serum total homocys- teine levels in confirmed Alzheimer disease. Arch Neurol 55, 1449-1455.
86. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA (2002) Plasma ho- mocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346, 476-483.
87. Clarke R (1998) Homocysteine and cardiovascular disease. Overview. JCardiovasc Risk 5, 213-215.
88. Nilsson K, Gustafson L, Hultberg B (2007) Elevated plasma homocysteine concentration in elderly patients with mental illness is mainly related to the presence of vascular disease and not the diagnosis. Dement Geriatr Cogn Disord 24, 162-168.
89. Luo Y, Zhou X, Yang X, Wang J (2007) Homocysteine induces tau hyperphosphorylation in rats. Neuroreport 18, 2005-2008.
90. Zhu X, Smith MA, Honda K, Aliev G, Moreira PI, Nunomura A, Casadesus G, Harris PL, Siedlak SL, Perry G (2007) Vascular oxidative stress in Alzheimer disease. J Neurol Sci 257, 240-246.
91. de Lustig ES, Serra JA, Kohan S, Canziani GA, Famulari AL, Dominguez RO (1993) Copper-zinc superoxide dismutase activity in red blood cells and serum in demented patients and in aging. J Neurol Sci 115, 18-25.
92. Famulari AL, Marschoff ER, Llesuy SF, Kohan S, Ser- ra JA, Dominguez RO, Repetto M, Reides C, Sacerdote de LE (1996) The antioxidant enzymatic blood profile in Alzheimer's and vascular diseases. Their association and a possible assay to differentiate demented subjects and controls. J Neurol Sci 141, 69-78.
93. Ihara Y, Hayabara T, Sasaki K, Fujisawa Y, Kawada R, Ya- mamoto T, Nakashima Y, Yoshimune S, Kawai M, Kibata M, Kuroda S (1997) Free radicals and superoxide dismutase in blood of patients with Alzheimer's disease and vascular dementia. J Neurol Sci 153, 76-81.
94. Foy CJ, Passmore AP, Vahidassr MD, Young IS, Lawson JT (1999) Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. QJM92, 39-45.
95. Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, Havlik R, White LR (2000) Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 54, 1265-1272.
96. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC (2004) Reduced risk of Alzheimer disease in users ofantioxidant vitamin supplements: the Cache County Study. Arch Neurol 61, 82-88.
97. Radak Z, Chung HY, Goto S (2008) Systemic adaptation to oxidative challenge induced by regular exercise. Free Radic Biol Med 44, 153-159.
98. RadakZ, Kaneko T, Tahara S, Nakamoto H, PucsokJ, Sasvari M, Nyakas C, Goto S (2001) Regular exercise improves cognitive function and decreases oxidative damage in rat brain. Neurochem Int 38, 17-23.
99. Rovio S, Kareholt I, Helkala EL, Viitanen M, Winblad B, Tuomilehto J, Soininen H, Nissinen A, Kivipelto M (2005) Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol 4, 705-711.
100. Larson EB, Wang L, Bowen JD, McCormick WC, Teri L, Crane P, Kukull W (2006) Exercise is associated with reduced risk for incident dementia among persons 65 years ofage and older. Ann Intern Med 144, 73-81.
101. Ho PI, Collins SC, Dhitavat S, Ortiz D, Ashline D, Rogers E, Shea TB (2001) Homocysteine potentiates beta-amyloid neurotoxicity: role ofoxidative stress. JNeurochem 78, 249-253.